High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation

Table 2 Baseline characteristics of propensity-matched patients with low- and high-dose Hepatitis B Immunoglobulin who met and did not meet the Milan criteria

Characteristic	Met the Milan criteria (38 pairs)			Did not meet the Milan criteria (18 pairs)
	Low-dose HBIG	High-dose HBIG	P value	Low-dose HBIG	High-dose HBIG	P value
	(n = 38)	(n = 38)		(n = 18)	(n = 18)
Age (yr)	52.7 ± 5.5	53.4 ± 8.1	0.643	52.9 ± 8.0	53.3 ± 8.6	0.917
Sex (male/female)	32/6	29/9	0.453	16/2	16/2	1.000
Child-Pugh score	6 (5-12)	6 (5-12)	0.710	6 (5-13)	6 (5-13)	0.932
AFP (ng/mL)	22.6 (2.0-8891.8)	15.3 (1.8-3811.2)	0.658	34.6 (3.5-31142.9)	112.5 (2.9-57348.8)	0.500
Number of tumors	1 (1-3)	1 (1-3)	0.963	1 (1-5)	1 (1-5)	0.811
Largest tumor size (cm)	2.2 (0.8-4.5)	2.1 (0.8-4.0)	0.994	5.75 (1.6-13.0)	4.9 (1.1-25.0)	0.393
Edmond-Steiner grade (I, II/III, IV)	17/21	17/21	1.000	4/14	2/16	0.500
Major vessel invasion (absent/present)	38/0	38/0	N/A	12/6	13/5	1.000
Microvascular invasion (absent/present)	23/15	26/12	0.664	5/13	4/14	1.000
Bile duct invasion (absent/present)	37/1	37/1	1.000	16/2	16/2	1.000
Satellite nodule (absent/present)	26/12	29/9	0.648	6/12	5/13	1.000

Values are presented as number/number, mean ± SD or median (range). AFP: Alpha-fetoprotein; N/A: Not applicable.